5 results about "Platelet factor" patented technology

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

This invention relates to a heparin anticoagulant oligosaccharide with low thrombocytopenia-inducing activity, its preparation method, and its application, belonging to the field of biomedical technology. The heparin anticoagulant oligosaccharide with low thrombocytopenia-inducing activity comprises an AT-binding sequence and a -GlcNS(6S)-GlcA2S- or -GlcNS(6S)-IdoA2S- linker sequence, specifically heparin anticoagulant dodecanosaccharide 12I-2, heparin anticoagulant dodecanosaccharide 12G-1, or heparin anticoagulant dodecanosaccharide 12G-2. This invention also provides methods for preparing heparin anticoagulant dodecanosaccharides 12I-2, 12G-1, and 12G-2, and their applications in the preparation of safe and effective anticoagulant and antithrombotic drugs. The heparin anticoagulant oligosaccharide designed in this invention is a specific dodecanoic acid molecule. By optimizing its sugar chain length, key structural domains and spatial conformation, its ability to form pathogenic H / PF4 complexes with platelet factor 4 (PF4) is weakened to the greatest extent. In clinical anticoagulation applications, it has a significant safety advantage in reducing the incidence of HIT and related fatal thrombosis (HITT).

Provided is a recombinant fibronectin fusion protein comprising a recombinant fibronectin mutant and platelet factor 4, wherein the recombinant fibronectin fusion protein has an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4, and a molecular weight of not more than 90 kDa. The recombinant fibronectin fusion protein exhibits good solubility, has a simple preparation process, and is conveniently purified. The recombinant fibronectin fusion protein comprises a new recombinant fibronectin, and can inhibit inflammation during wound healing, and promote cutaneous wound healing in mice. When platelet factor 4 is fused to the N-terminus of the recombinant fibronectin mutant, cell proliferation activity can be significantly and effectively enhanced.

The disclosure refers to reagents, kits and methods for detecting anti-PF4 antibodies and diagnosing thrombotic events not induced by heparin, including vaccine-induced thrombotic thrombocytopenia. The method provided by the disclosure comprises: (i) contacting whole blood. plasma or serum sample obtained from a subject with a reagent comprising: (a) a binding molecule selected from the group consisting of platelet factor 4 protein (PF4), a fragment of PF4 which can bind anti-PF4 antibodies, and an anti-idiotype antibody of anti-platelet factor 4 antibodies (anti-PF4 antibodies); and (b) a solid support, wherein the binding molecule (a) is covalently bound to the surface of the solid support (b), and wherein the binding molecule (a) does not include heparin or a heparin surrogate, and (ii) analysing the sample to detect a complex formed by the reagent and the anti-PF4 antibodies, wherein detecting the complex is indicative of the sample containing anti-PF4 antibodies.

The present application relates to the use of platelet factor 4 in the preparation of a drug for treating or preventing Candida albicans infection, platelet factor 4 acts on macrophage CXCR3 receptor, antagonizes Candida albicans induced macrophage PANoptosis, thereby reducing the damage of Candida albicans to macrophages, maintaining the survival and normal function of macrophages, enhancing the clearance ability of the body to Candida albicans, reducing the inflammatory response caused by infection, reducing pathological damage, and different from the treatment mechanism of traditional antifungal drugs, the present application does not directly act on fungi, which helps to reduce the formation of drug-resistant strains and the toxic side effects such as liver toxicity and kidney toxicity caused by antifungal drugs, and can provide a more optimal new treatment mode for clinical Candida albicans infection.